Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

NCT01616277
View directory record Official record
Conditions
Healthy
Interventions
PF-06252616, Placebo, PF-06252161
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

NCT02452801
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

NCT07141199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

NCT01152671
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

NCT01462851
View directory record Official record
Conditions
Healthy
Interventions
PF-05297909 25 mg, PF-05297909 100 mg, PF-05297909 250 mg, PF-05297909 525 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

NCT02650895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Efprezimod alfa, Saline
Biological · Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 14, 2026, 4:32 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety of PAZ-417 in Healthy Elderly Adults

NCT00663065
View directory record Official record
Conditions
Healthy
Interventions
PAZ-417
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

NCT01611467
View directory record Official record
Conditions
Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions
CC-223
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

NCT00607906
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

NCT05745207
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

NCT03381664
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

NCT03228433
View directory record Official record
Conditions
Healthy Participants
Interventions
TAK-418, TAK-418 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3015014, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

NCT01741493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-494, Placebo, Tofacitinib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants

NCT04729101
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Lansoprazole
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT02754830
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

NCT01593046
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection, GSK1265744 LAP 200mg intramuscular injection, GSK1265744 LAP 400mg intramuscular injection, TMC278 LA 1200mg intramuscular injection, TMC278 LA 600mg intramuscular injection
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744

NCT00659191
View directory record Official record
Conditions
HIV Infection
Interventions
GSK1265744
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

NCT02858973
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

NCT05552183
View directory record Official record
Conditions
Hepatic Impairment
Interventions
oral dose of 200 mg pacritinib twice daily (BID)
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of TD-1439 in Healthy Subjects

NCT02903095
View directory record Official record
Conditions
Healthy Subjects
Interventions
TD-1439, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants

NCT07599761
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of CDX-0159

NCT04146129
View directory record Official record
Conditions
Healthy Subjects
Interventions
CDX-0159, Normal saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 14, 2026, 4:32 AM EDT